Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Parasitic Diseases

• Publication date

  2010-10-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12639-010-0012-5PMID 21966123PMCID PMC3081735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome.

  2009cited by this paper
• Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.

  2009cited by this paper
• Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.

  2008cited by this paper
• Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.

  2007cited by this paper
• Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.

  2007cited by this paper
• Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice.

  2007cited by this paper
• Enhanced Protection against Malaria by a Chimeric Merozoite Surface Protein Vaccine

  2006cited by this paper
• Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.

  2006cited by this paper
• Immunoglobulin G2a isotype may have a protective role inPlasmodium berghei NK65 infection in immunised mice

  2004cited by this paper
• Progress in the development of recombinant and synthetic blood-stage malaria vaccines

  2003cited by this paper
• The pathogenic basis of malaria

  2002cited by this paper
• Fusogenic potential of prokaryotic membrane lipids. Implication in vaccine development.

  2001cited by this paper
• Fusogenic potential of prokaryotic membrane lipids.

  2001cited by this paper
• Differential effect of anti-B7-1 and anti-M150 antibodies in restricting the delivery of costimulatory signals from B cells and macrophages.

  1998cited by this paper
• Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens

  1997cited by this paper
• Identification of a Plasmodium berghei antigen sharing common features with P. falciparum and P. chabaudi parasitophorous-vacuole membrane antigens

  1996cited by this paper
• Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.

  1996cited by this paper
• Adjuvants for human vaccines--current status, problems and future prospects.

  1995cited by this paper
• Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine.

  1994cited by this paper
• Proteins on the surface of the malaria parasite and cell invasion

  1994cited by this paper
• A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies.

  1994cited by this paper
• Rosetting Plasmodium falciparum-infected erythrocytes express unique strain-specific antigens on their surface

  1993cited by this paper
• Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum

  1992cited by this paper
• A reticulocyte-binding protein complex of Plasmodium vivax merozoites.

  1992cited by this paper
• Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein.

  1991cited by this paper
• Malaria: Principles and Practice of Malariology

  1989cited by this paper
• Host cell specificity and schizogony of Plasmodium berghei under different in vitro conditions.

  1989cited by this paper
• Major animal models in malaria research: rodent.

  1988cited by this paper
• Vaccination of mice against malaria with soluble antigens. I. The effect of detergent, route of injection, and adjuvant

  1986cited by this paper
• Characteristics of the protective response of BALB/c mice immunized with a purified Plasmodium yoelii schizont antigen.

  1983cited by this paper
• The isolation and fractionation of malaria-infected cells.

  1977cited by this paper
• Malaria (Plasmodium knowlesi) merozoites: immunity and the surface coat.

  1975cited by this paper
• Properties of Protective Malarial Antibody

  1970cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970influential reference
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Protein Profile and Hematological Parameters of Mice post Injected with Irradiated Plasmodium berghei

  2016cites this paper
• CD4+T Cells Expansion in P. berghei (NK-65) Infected and Immunized BALB/C Mice

  2015cites this paper
• 43 kDa and 66 kDa, two blood stage antigens induce immune response in Plasmodium berghei malaria.

  2014cites this paper
• The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment

  2013cites this paper
• Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer

  2012cites this paper